HPC and CFU Escape SLT-1 Toxicity
| (A) Analysis of HPC . | ||
|---|---|---|
| Patient Source of Mobilized Blood . | Percentage of CD34+45lo HPC at Day 6-7 . | |
| Untreated . | SLT-1–Treated . | |
| Breast cancer | ||
| Unfractionated | 2.8% | 2.6% |
| HPC-enriched | 39.5% | 60.2% |
| Lymphoma | ||
| Unfractionated | 1.1% | 1.4% |
| HPC-enriched | 71.1% | 39.5% |
| Myeloma | ||
| HPC-enriched | 5.0% | 28.4% |
| (B) Analysis of CFC | ||
| Patient Source of Mobilized Blood | No. of Colonies/100-200 Cells Plated at Day 203-150 | |
| Untreated | SLT-1–Treated | |
| Breast cancer | ||
| HPC-enriched | 15 ± 1 | 13 ± 1 |
| Lymphoma | ||
| HPC-enriched | 17 ± 1 | 20 ± 1.5 |
| Myeloma | ||
| HPC-enriched | 17 ± 1 | 19 ± 1 |
| (A) Analysis of HPC . | ||
|---|---|---|
| Patient Source of Mobilized Blood . | Percentage of CD34+45lo HPC at Day 6-7 . | |
| Untreated . | SLT-1–Treated . | |
| Breast cancer | ||
| Unfractionated | 2.8% | 2.6% |
| HPC-enriched | 39.5% | 60.2% |
| Lymphoma | ||
| Unfractionated | 1.1% | 1.4% |
| HPC-enriched | 71.1% | 39.5% |
| Myeloma | ||
| HPC-enriched | 5.0% | 28.4% |
| (B) Analysis of CFC | ||
| Patient Source of Mobilized Blood | No. of Colonies/100-200 Cells Plated at Day 203-150 | |
| Untreated | SLT-1–Treated | |
| Breast cancer | ||
| HPC-enriched | 15 ± 1 | 13 ± 1 |
| Lymphoma | ||
| HPC-enriched | 17 ± 1 | 20 ± 1.5 |
| Myeloma | ||
| HPC-enriched | 17 ± 1 | 19 ± 1 |
Mobilized MNC were treated with 5 μg/mL SLT-1 for 60 minutes, washed, and cultured. For HPC assays, toxin-treated or untreated cells were cultured in Myelocult + 10% Hemostim culture medium for 7 days, followed by harvest of cultured cells and staining with anti-CD34-PE and anti-CD45-QR conjugates. Mobilized MNC were enriched for HPC by negative selection after antibody coating and magnetic bead depletion resulting in a cell population in which 40% to 60% of cells display the HPC phenotype.
Cells were plated in microtiter wells. Values listed represent the average number of colonies (±SE) calculated from 6 to 12 replicate wells for each condition tested.